What is the main purpose of this 8-K filing?

The primary purpose of this 8-K filing is to officially release Amgen's unaudited financial results for the fourth quarter and the full fiscal year 2024. It includes a press release that details the company's operational and financial performance for these periods, along with its financial position at year-end 2024.

What are non-GAAP financial measures, and why does Amgen use them?

Non-GAAP financial measures are financial metrics that exclude certain items from GAAP (Generally Accepted Accounting Principles) results. Amgen uses them, such as non-GAAP earnings per share and operating income, to provide investors with a more insightful view of the company's core operational performance. They are intended to facilitate comparisons of results across different periods by excluding items that may be volatile or not indicative of ongoing business operations, like acquisition-related costs and restructuring charges.

What specific types of expenses does Amgen exclude in its non-GAAP calculations?

Amgen excludes several categories of expenses in its non-GAAP calculations. These include acquisition-related expenses (such as amortization of acquired intangibles and fair value adjustments to acquired inventory), net charges related to restructuring and cost savings initiatives (like facility impairments and severance costs), and other items deemed outside the ordinary course of business (such as gains/losses on investments and certain legal settlement costs). Detailed reconciliations are provided in the earnings press release.

Besides non-GAAP earnings, what other financial metrics does Amgen highlight?

In addition to non-GAAP measures, Amgen also highlights Free Cash Flow (FCF), which is calculated as operating cash flow minus capital expenditures. They also present a debt leverage ratio, defined as total GAAP debt divided by EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) for the full year 2024. These metrics are intended to provide further insight into the company's liquidity and financial structure.

AMGN 8-K: Earnings & Results

Summary

Amgen Inc. (AMGN) filed an 8-K on February 4, 2025, primarily to furnish its Fourth Quarter and Full Year 2024 earnings press release. This filing provides investors with the company's unaudited financial results for the periods ending December 31, 2024. A key aspect of the release is its presentation of non-GAAP financial measures, which Amgen uses to offer a supplemental view of its performance, facilitating comparisons across periods by excluding items such as acquisition-related expenses, restructuring costs, and certain other irregular income and expenses. The company also presented Free Cash Flow (FCF) and a debt leverage ratio (debt to EBITDA) as additional metrics. Management believes these non-GAAP measures, alongside GAAP results, provide a more comprehensive understanding of Amgen's ongoing operational performance and liquidity. Investors should review the accompanying press release for detailed reconciliations of these non-GAAP figures to their GAAP equivalents and to understand the specific adjustments made, which include the treatment of acquired intangible assets and integration costs related to acquisitions.

Key Highlights

1Amgen released its unaudited Fourth Quarter and Full Year 2024 financial results on February 4, 2025.
2The filing includes a press release detailing the company's financial performance and position as of December 31, 2024.
3Amgen presents several non-GAAP financial measures, including non-GAAP earnings per share, operating income, and operating margin.
4Key non-GAAP adjustments include acquisition-related expenses, restructuring and cost savings initiatives, and other items deemed outside the ordinary course of business.
5The company also provided Free Cash Flow (FCF) and a debt leverage ratio (debt to EBITDA) as supplemental metrics.
6Amgen states that these non-GAAP measures are intended to enhance investor understanding and facilitate performance comparisons.
7The press release contains reconciliations of non-GAAP measures to their most directly comparable GAAP financial measures.

AMGEN INC 8-K Report, Financial Results (Feb 4, 2025)

Summary

Key Highlights

Frequently Asked Questions